TS

Tushar Sharma

Active Director Director DIN 10433159
DIN 10433159 First appointment Dec 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2023
Shareholding value •••• Premium profile

About Tushar Sharma

Data last updated:

Tushar Sharma is a Director at Meulyf Pharmaceuticals Private Limited (since 2023). The company operates in Pharma. Meulyf Pharmaceuticals Private Limited reported revenue of ₹84,552 (FY 2025).

DIN 10433159
Primary Designation Director
Industry Pharma
First Appointment 20 Dec 2023
Oldest Company Age 2 yrs
Largest company Meulyf Pharmaceuticals Private Limited · ₹84,552 (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director20 Dec 20232023₹84,552 (FY 2025)Active

Board colleagues of Tushar Sharma

NameDINCompanyDesignation
Ritik Gupta10433160Meulyf Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Meulyf Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Tushar Sharma

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Tushar Sharma

Tushar Sharma currently holds 1 directorship: Meulyf Pharmaceuticals Private Limited (Director, since 20 Dec 2023, revenue ₹84,552 (FY 2025)).

Tushar Sharma was first appointed on 20 Dec 2023 as Director at Meulyf Pharmaceuticals Private Limited.

The current boards of Tushar Sharma's companies include Ritik Gupta (Meulyf Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available